PRELIMINARY TWO-YEAR EFFICACY RESULTS FROM A RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY OF TWO DIFFERENT SIROLIMUS (SRL) REGIMENS VERSUS A TACROLIMUS (TAC) + MYCOPHENOLATE REGIMEN (MMF) IN DE NOVO RENAL ALLOGRAFT RECIPIENTS: 531